STATCenter·
STAT+: Biotech’s rebound isn’t lifting all boats equally
Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.
Read at STAT →
Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.

<iframe src="https://statesidedaily.com/embed/cluster/4f6d0f544eb0d7c950eae0ec45782e815e7ad4aa" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Biotech’s rebound isn’t lifting all boats equally"></iframe>